BTL Industries v. EMSZERO: Default Judgment & Permanent Injunction in Body-Contouring Patent Case

Introduction

In a decisive ruling issued April 11, 2025, the U.S. District Court for the District of Delaware granted BTL Industries, Inc. a default judgment against EMSZERO Beauty Inc., awarding $100,000 in statutory damages, finding willful patent infringement, and issuing a sweeping permanent injunction covering body-contouring devices. Case No. 1:24-cv-00864 closed after just 261 days — a notably swift resolution — and stands as a stark warning to overseas device manufacturers attempting to exploit established medical aesthetics brand equity in the U.S. market.

The case involved two utility patents protecting BTL’s flagship electromagnetic muscle-stimulation technology, a sprawling product line of accused EMSZERO-branded devices, and trademark violations spanning some of the most recognizable names in the body-contouring industry: EMSCULPT®, EMSCULPT NEO®, EM®, and HIFEM®. For patent attorneys, IP managers, and R&D teams operating in the medical aesthetics or consumer wellness device space, this case delivers critical lessons in default judgment strategy, trademark-patent overlap, and enforcement against online marketplace infringers.

Case Overview

The Parties

The Patents at Issue

This landmark case involved two utility patents protecting BTL’s flagship electromagnetic muscle-stimulation technology:

• • U.S. Patent No. 10,478,634 — Covers electromagnetic field-based muscle stimulation apparatus and methods.
• • U.S. Patent No. 11,679,255 — A continuation protecting refined HIFEM device configurations and therapeutic applications.

Together, the Asserted Patents protect the core HIFEM technology underlying BTL’s commercially dominant body-sculpting product family.

The Accused Products

EMSZERO marketed over 25 product variants — from portable home-use sculpting machines to professional 5-in-1 devices — bearing names and trademarks virtually identical to BTL’s registered marks. The accused product line included the EMSZERO Neo Personal Sculpting Pro, EMSZERO PowerFlex HI-EMT Muscle Stimulator, and EMSzero Facial Therapy Machine, sold primarily through the website emszerobeauty.com and the domain emszero.shop.

Legal Representation

BTL was represented by Richard Charles Weinblatt and Seth R. Ogden of Stamoulis & Weinblatt LLC, a Delaware-based IP litigation firm. No defense counsel appeared on behalf of EMSZERO.

Litigation Timeline & Procedural History

BTL Industries filed suit on July 24, 2024, in the District of Delaware — a strategic and predictable venue choice given Delaware’s status as the preeminent U.S. jurisdiction for corporate IP disputes, its experienced patent bench, and efficient docket management.

The case closed on April 11, 2025, yielding a total litigation duration of 261 days from filing to final judgment. This compressed timeline is directly attributable to EMSZERO’s failure to appear or retain defense counsel at any stage of the proceedings. The absence of a defendant engaging in active litigation — no answer, no motion practice, no discovery disputes — allowed the court to move swiftly to default judgment procedures under Federal Rule of Civil Procedure 55.

The matter was presided over by Chief Judge Colm F. Connolly of the Delaware District Court, a jurist with extensive familiarity with complex patent litigation and a track record of efficient case management in IP matters.

The procedural trajectory followed a straightforward path: complaint filed, defendant failed to respond within the required period, plaintiff moved for entry of default, and subsequently filed a Motion for Default Judgment supported by evidentiary submissions establishing infringement, willfulness, and damages.

The Verdict & Legal Analysis

Outcome

Chief Judge Connolly granted BTL’s Motion for Default Judgment in its entirety. The court’s order encompasses several critical components:

• Damages: The court awarded $100,000 in statutory damages pursuant to 15 U.S.C. § 1117(c) based on EMSZERO’s use of a counterfeit mark.
• Patent Infringement: Default judgment was entered finding EMSZERO directly and indirectly infringed both U.S. Patent Nos. 10,478,634 and 11,679,255, with an express finding of willful infringement.
• Trademark Infringement: The court found EMSZERO’s use of EMSCULPT®, EMSCULPT NEO®, EM®, and HIFEM® — or confusingly similar variations — violated the Lanham Act, the Delaware Deceptive Trade Practices Act, and Delaware Common Law.
• Permanent Injunction: EMSZERO, its officers, agents, and those acting in concert are permanently enjoined from using, making, selling, offering to sell, or importing infringing devices, and from using BTL’s trademarks or confusingly similar marks in connection with body-contouring products.

Verdict Cause Analysis

Because EMSZERO defaulted, the court accepted BTL’s well-pleaded factual allegations as admitted. The willfulness finding — significant for both patent and trademark purposes — followed from the deliberate nature of EMSZERO’s conduct: manufacturing and marketing products under names nearly identical to protected trademarks while incorporating patented HIFEM technology without authorization.

The court’s injunction is notable for its operational reach, ordering EMSZERO to withdraw all products from U.S. distribution channels, destroy infringing inventory, and retract all online advertising. Critically, the court also directed Alibaba Cloud Computing Ltd. (as domain registrar) to lock and suspend the emszero.shop domain and ordered Cloudflare, Inc. to take down the associated website — reflecting modern enforcement mechanisms targeted at the digital infrastructure of online infringers.

Legal Significance

While default judgments carry limited direct precedential weight on substantive patent law questions — given that no claim construction or validity analysis was litigated — this case is significant procedurally and strategically. It demonstrates the Delaware court’s willingness to:

• Issue broad technology-plus-trademark injunctions in body-contouring patent cases.
• Extend injunctive relief to third-party internet infrastructure providers (domain registrars and CDN providers).
• Sustain willfulness findings and statutory damages on default where counterfeit conduct is evident.

Strategic Takeaways

For Patent Holders: Default judgment remains a powerful and efficient enforcement tool against non-appearing defendants, particularly foreign-based online sellers. Combining patent and trademark claims maximizes both damages exposure and the breadth of injunctive relief available.

For Accused Infringers: Failure to appear is never a neutral act. A default judgment with willfulness findings and a permanent injunction creates lasting legal liability, destroys the ability to re-enter the U.S. market, and enables the plaintiff to pursue asset enforcement globally.

For R&D Teams: Products mimicking established HIFEM-branded devices — even under modified names — carry extreme patent and trademark exposure. Any electromagnetic muscle-stimulation product entering the U.S. market requires a thorough Freedom to Operate (FTO) analysis against BTL’s patent portfolio, including continuation patents in the US17/930888 family.

Industry & Competitive Implications

The medical aesthetics device market — particularly non-invasive body-contouring — is intensely competitive, with established players like BTL defending substantial R&D investment through layered IP portfolios. The proliferation of lower-cost EMSZERO-branded knockoffs on online marketplaces represents a recognized enforcement challenge for premium device manufacturers.

This case signals that BTL is actively monitoring and litigating against such infringers in U.S. federal court rather than relying solely on marketplace takedown mechanisms. The order targeting Alibaba Cloud and Cloudflare directly reflects a broader enforcement trend: plaintiffs are pursuing the digital supply chain, not merely the end seller.

For companies operating in adjacent spaces — including home-use EMS devices, facial electromagnetic stimulation machines, and hybrid body-sculpting platforms — BTL’s patent portfolio (particularly its continuation strategy around US17/930888) represents a significant FTO consideration. Licensing conversations with BTL may become increasingly relevant for legitimate device manufacturers seeking U.S. market access in the HIFEM technology space.

Frequently Asked Questions

What patents were involved in BTL Industries v. EMSZERO Beauty?

The case involved U.S. Patent Nos. 10,478,634 and 11,679,255, both protecting High-Intensity Focused Electromagnetic (HIFEM) muscle-stimulation technology underlying BTL’s EMSCULPT® product family.

What was the basis for the default judgment in this case?

EMSZERO Beauty failed to appear, file an answer, or retain defense counsel. Under Fed. R. Civ. P. 55, the court accepted BTL’s allegations as admitted and granted default judgment, including a willful infringement finding and permanent injunction.

How might this verdict affect body-contouring device patent litigation?

The case reinforces that U.S. courts will issue broad injunctions — including against internet infrastructure providers — in patent-plus-trademark infringement cases, and signals active enforcement by BTL against online marketplace sellers of HIFEM-based devices.